Scientists Identify Potential Therapeutic Target For Colon Cancer

University of North Carolina at Chapel Hill School of Medicine scientists have identified potential therapeutic target for drug-resistant colon cancer.

The researchers aim at blocking a molecule found on the surface of cells.

Prescription Drug Costs - Not a Worry for Many Colon Cancer Patients
A majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs

Drugs that target the epidermal growth factor receptor, or EGFR, have been used for a number of cancers.

But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.

According to Dr David Threadgill, adjunct professor in the department of genetics at UNC and lead author of the study, drugs that target the closely related receptor ERBB3 would probably be much more effective than EGFR inhibitors at treating most colorectal cancers.

Researchers Develop Novel Method To Digitally Detect Methylated DNA In Colon Cancer
A unique and highly sensitive method for detecting methylation-associated cancers has been demonstrated by a study published in this week's online issue of Nature Biotechnology.

During the study, the researchers genetically blocked ERBB3 in a mouse model of colon cancer and in human colon cancer cell lines.

"If you genetically remove ERBB3, as you would if you were pharmacologically targeting it, then the mice rarely develop colon cancer," said Threadgill.

How Two Genes Promote Colon Cancer's Growth
American scientists have shed new light on how two cancer-promoting genes enhance a tumour's capacity to grow and survive under conditions where normal cells die.

In the human colon cancer cell lines that are resistant to EGFR inhibitors, cell death increased dramatically when ERBB3 was genetically removed.

"So ERBB3 is essential for preventing colon cancer cells from dying," Threadgill said.

Threadgill is conducting further studies for testing a pharmacologic inhibitor to get the same anti-ERBB3 effect they achieved with genetics.

"If we can use an inhibitor to block ERBB3, then it should be a very potent anti-cancer therapeutic," he added.

The study appears in Journal of Clinical Investigation.

Source-ANI
ARU